Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
Top Page
Neuren Pharmaceuticals Limited
(Sydney:NEU)
Select Model
Select Model
Rating:59Neutral
Price Target:
AU$12.00
▲(1.87% Upside)
Action:ReiteratedDate:03/01/26
The score is primarily supported by strong recent profitability and a debt-free balance sheet, but is materially offset by a pronounced technical downtrend and a high P/E valuation. Revenue and cash flow volatility further reduce confidence in the stability of recent results.
Positive Factors
Debt-free balance sheet
A debt-free, conservatively positioned balance sheet materially lowers financial risk and preserves strategic optionality. For a clinical-stage biotech with lumpy receipts, no debt reduces near-term liquidity stress, enables self-funding or opportunistic M&A, and supports sustained R&D investment over cycles.
Negative Factors
Sharp revenue volatility
Large year-to-year swings in revenue reduce visibility for multi-year R&D planning and budgeting. For a small biotech, volatile top-line inflows complicate trial financing and can force defensive actions (delayed programs or fundraising) that impair long-term development timelines and strategic execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free, conservatively positioned balance sheet materially lowers financial risk and preserves strategic optionality. For a clinical-stage biotech with lumpy receipts, no debt reduces near-term liquidity stress, enables self-funding or opportunistic M&A, and supports sustained R&D investment over cycles.
Read all positive factors
Neuren Pharmaceuticals Limited (NEU) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.49B
Dividend YieldN/A
Average Volume (3M)305.98K
Price to Earnings (P/E)78.4
Beta (1Y)2.32
Revenue Growth12.35%
EPS Growth26.73%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.12
Shares Outstanding126,639,530
10 Day Avg. Volume278,541
30 Day Avg. Volume305,983
Financial Highlights & Ratios
PEG Ratio-1.00
Price to Book (P/B)7.05
Price to Sales (P/S)36.92
P/FCF Ratio19.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$25.31Price Target Upside114.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.15
Revenue Forecast (FY)AU$83.75M
Neuren Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has compl...
How the Company Makes Money
Neuren primarily makes money through partnering and licensing arrangements related to its drug assets. A key revenue stream is derived from its collaboration with Acadia Pharmaceuticals for trofinetide/DAYBUE, under which Neuren is entitled to rec...
Neuren Pharmaceuticals Limited Earnings Call Summary
Earnings Call Date:Feb 29, 2024
(Q4-2023)
| % Change Since: |
Next Earnings Date:Aug 25, 2026
Earnings Call Sentiment Positive
The earnings call highlighted Neuren's strong financial performance, significant cash growth, and successful collaboration with Acadia. Positive trial results for NNZ-2591 and an expanded global reach were significant achievements. However, challenges such as tax liabilities, exchange rate impacts, and share price volatility were noted. Overall, the positive aspects and strategic advancements overshadow the lowlights.Positive Updates
Record Profit and Cash Growth
Neuren reported a profit of AUD 157 million, with cash growing from $40 million to $229 million without any capital raising.
Negative Updates
Exchange Rate Impact
There was an $8.2 million expense due to exchange losses, partially offset by foreign exchange gains.
Read all updates
Q4-2023 Updates
Positive
Negative
Record Profit and Cash Growth
Neuren reported a profit of AUD 157 million, with cash growing from $40 million to $229 million without any capital raising.
Read all positive updates
Company Guidance
During Neuren's 2023 earnings call, CEO Jonathan Pilcher highlighted several key financial metrics. The company reported a profit of AUD 157 million, fueled by AUD 27 million in royalty income, a USD 59 million milestone payment from DAYBUE's first commercial sale in the U.S., and USD 146 million from an expanded deal with Acadia. Cash reserves increased from AUD 40 million to AUD 229 million without any capital raising. Neuren anticipates royalty income between AUD 61 million and AUD 70 million next year, based on a royalty rate that ranges from 10% to 12%. Additionally, Neuren is expecting USD 50 million in milestone payments as DAYBUE's sales exceed USD 250 million. Neuren's R&D expenses totaled AUD 27 million, with significant efforts directed towards four Phase II trials and preparations for Phase III. Acadia's DAYBUE guidance for 2024 forecasts USD 370 million to USD 420 million in sales, indicating substantial growth from 2023's USD 177 million.Neuren Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
88
Very Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 64.63M | 213.24M | 231.93M | 14.55M | 3.20M |
| Gross Profit | 64.61M | 213.22M | 205.17M | 14.54M | 3.19M |
| EBITDA | 22.05M | 175.57M | 199.26M | -670.00K | -10.98M |
| Net Income | 30.44M | 142.04M | 157.08M | 184.00K | -7.79M |
Balance Sheet | |||||
| Total Assets | 342.86M | 409.71M | 247.97M | 43.27M | 40.06M |
| Cash, Cash Equivalents and Short-Term Investments | 296.12M | 222.24M | 228.54M | 40.18M | 36.78M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.41M | 45.80M | 42.76M | 1.68M | 803.00K |
| Stockholders Equity | 338.45M | 363.90M | 205.21M | 41.59M | 39.25M |
Cash Flow | |||||
| Free Cash Flow | 125.39M | -11.28M | 184.88M | 3.58M | -9.98M |
| Operating Cash Flow | 125.42M | -11.27M | 184.93M | 3.60M | -9.97M |
| Investing Cash Flow | -88.01M | 4.13M | -211.49M | -19.00K | -10.00K |
| Financing Cash Flow | -33.22M | -8.78M | 3.62M | -2.00K | 22.18M |
Neuren Pharmaceuticals Limited Technical Analysis
Negative
11.78
Price Trends
13.67
Negative
16.44
Negative
17.12
Negative
Market Momentum
-0.57
Negative
42.64
Neutral
82.41
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NEU, the sentiment is Negative. The current price of 11.78 is below the 20-day moving average (MA) of 11.96, below the 50-day MA of 13.67, and below the 200-day MA of 17.12, indicating a bearish trend. The MACD of -0.57 indicates Negative momentum. The RSI at 42.64 is Neutral, neither overbought nor oversold. The STOCH value of 82.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NEU.
Neuren Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$496.99M | 14.96 | 13.29% | 0.38% | 7.76% | 1.55% | |
59 Neutral | AU$1.49B | 78.41 | 9.20% | ― | 12.35% | 26.73% | |
52 Neutral | AU$2.72B | ― | -18.31% | ― | 198.58% | 3.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | AU$203.48M | -12.98 | -44.80% | ― | 42.05% | -0.84% | |
41 Neutral | AU$87.00M | -2.12 | -30.19% | ― | ― | 63.46% | |
40 Underperform | AU$70.74M | -3.40 | -35.86% | ― | ― | -19.21% |
* Healthcare Sector Average
AU:NEU
Neuren Pharmaceuticals Limited
11.78
-0.15
-1.26%
AU:CUV
Clinuvel Pharmaceuticals
9.90
-1.50
-13.19%
AU:MSB
Mesoblast Limited
2.11
0.15
7.65%
AU:OCC
Orthocell Ltd
0.75
-0.75
-50.00%
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:IMM
Immutep Ltd
0.05
-0.23
-82.86%
Neuren Pharmaceuticals Limited Corporate Events
Neuren updates market on ongoing on‑market share buy‑back
Mar 23, 2026
Neuren Pharmaceuticals Limited is an Australian biopharmaceutical company listed on the ASX under the code NEU. It focuses on developing and commercialising pharmaceutical therapies, with its ordinary fully paid shares actively traded in the marke...
Neuren Updates Market on Ongoing On-Market Share Buy-Back
Mar 12, 2026
Neuren Pharmaceuticals Limited has provided an updated notice to the ASX regarding its ongoing on-market share buy-back program for its ordinary fully paid shares. The latest daily notification, dated 13 March 2026, confirms that a total of 72,500...
Neuren director Joseph Basile lifts stake with on-market share purchase
Mar 5, 2026
Neuren Pharmaceuticals has disclosed a change in the shareholding of director Joseph Basile, who increased his direct interest in the company through an on-market trade. Basile acquired 12,300 ordinary shares on 5 March 2026 at $12.34 per share, l...
Neuren backs Acadia’s EMA appeal after CHMP rejection of Rett drug trofinetide
Mar 2, 2026
Neuren Pharmaceuticals said its partner Acadia Pharmaceuticals will seek a re-examination by the European Medicines Agency’s CHMP after the committee voted to refuse marketing authorisation for trofinetide to treat Rett syndrome in patients ...
Neuren Highlights Neurodevelopmental Focus and Development Risks in Investor Update
Feb 27, 2026
Neuren Pharmaceuticals has released an investor presentation highlighting its mission to improve the lives of people with neurodevelopmental disabilities through targeted drug development programs. The company also underscores the significant risk...
Neuren Builds Cash and Pipeline as DAYBUE Royalties Climb in 2025
Feb 27, 2026
Neuren Pharmaceuticals reported 2025 royalty income of A$65 million from Rett syndrome drug DAYBUE, up 15% year on year, and a profit after tax of A$30 million, with cash and short-term investments rising to A$296 million. Although profit declined...
Neuren profit falls on absence of one-offs as core royalties and R&D spend climb
Feb 27, 2026
Neuren Pharmaceuticals reported a sharp fall in reported revenue and profit for 2025, reflecting the absence of large one-off payments booked in the prior year, even as its core royalty stream and interest income continued to grow. Total revenue f...
Neuren Rides DAYBUE Growth as 2025 Royalties Climb and 2026 Outlook Strengthens
Feb 26, 2026
Neuren Pharmaceuticals reported strong financial momentum driven by the continued uptake of DAYBUE in the U.S., as Acadia recorded 2025 net sales of US$391 million, up 12% year-on-year, and Q4 sales of US$110 million, a quarterly record supported ...
Neuren Pharmaceuticals Launches On-Market Share Buy-Back
Feb 11, 2026
Neuren Pharmaceuticals Limited has announced a new on-market share buy-back of its ordinary fully paid shares listed on the ASX under the code NEU. The move signals that the board sees value in the current share price and is willing to deploy capi...
Neuren Schedules Investor Webinar as Rare Neurology Portfolio Advances
Feb 11, 2026
Neuren Pharmaceuticals will host an investor webinar on 12 February 2026 to discuss recently announced business updates, offering investors an opportunity to engage directly with management and submit questions. The event underlines the company...
Neuren launches on-market buy-back as board flags undervalued shares
Feb 11, 2026
Neuren Pharmaceuticals has launched an on-market share buy-back program of up to 5% of its shares on issue, to be conducted over a period of up to 12 months under New Zealand companies law, with purchases and pricing at the company’s discret...
Neuren Doses First Patient in Landmark Phase 3 Trial for Phelan-McDermid Syndrome
Feb 5, 2026
Neuren Pharmaceuticals has dosed the first patient in its Koala Phase 3 clinical trial of NNZ-2591 for Phelan-McDermid syndrome, marking the first-ever Phase 3 study in this rare neurodevelopmental disorder, which currently has no approved treatme...
Neuren Set to Benefit as US Extends Rare Pediatric Disease Voucher Program to 2029
Feb 4, 2026
Neuren Pharmaceuticals has highlighted the reauthorization by the US Congress of the Rare Pediatric Disease Priority Review Voucher program through 30 September 2029, a move that preserves a lucrative incentive for developers of treatments for rar...
Neuren Gains FDA Feedback Charting NNZ-2591 Path in HIE and Pitt Hopkins
Feb 4, 2026
Neuren reported that FDA written feedback validated its planned IND-opening study for NNZ-2591 in hypoxic ischemic encephalopathy, contingent on additional juvenile animal data before a late-2026 start, while guidance for Pitt Hopkins syndrome con...
Neuren Faces EU Setback as EMA Panel Issues Negative Trend Vote on Trofinetide for Rett Syndrome
Feb 2, 2026
Neuren Pharmaceuticals disclosed that its licensee Acadia Pharmaceuticals has received a negative trend vote from the European Medicines Agency’s Committee for Medicinal Products for Human Use on the marketing authorization application for t...
Neuren Defends Timely Disclosure of Material DAYBUE Sales Projections to ASX
Jan 18, 2026
Neuren Pharmaceuticals has confirmed to the ASX that recent information disclosed by its partner Acadia Pharmaceuticals on projected DAYBUE net sales, including a substantial increase in expected 2028 revenue versus 2025 guidance, is materially im...
Neuren’s Partner Acadia Sees DAYBUE Sales Climbing to US$700m by 2028
Jan 14, 2026
Neuren Pharmaceuticals reported that its partner Acadia Pharmaceuticals is projecting global net sales of Rett syndrome therapy DAYBUE to reach about US$700 million in 2028, underpinned by the US rollout of the new DAYBUE STIX powder formulation, ...
Neuren Advances NNZ-2591 Program as Phase 2 PMS Data Published and Phase 3 Koala Trial Recruits in US
Jan 7, 2026
Neuren Pharmaceuticals has announced that results from its Phase 2 clinical trial of NNZ-2591 in children and adolescents with Phelan-McDermid syndrome have been published in the peer-reviewed journal Neurology Genetics, with the study reporting t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.